Atorvastatin, Ezetimibe — Competitive Intelligence Brief

Atorvastatin, Ezetimibe (Atorvastatin, Ezetimibe) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Statin and cholesterol absorption inhibitor combination. Area: Cardiovascular.

marketed Statin and cholesterol absorption inhibitor combination HMG-CoA reductase; NPC1L1 transporter Cardiovascular Small molecule

Target snapshot

Atorvastatin, Ezetimibe (Atorvastatin, Ezetimibe) — Abant Izzet Baysal University. Atorvastatin inhibits HMG-CoA reductase to lower LDL cholesterol, while ezetimibe blocks intestinal cholesterol absorption, providing dual lipid-lowering action.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Atorvastatin, Ezetimibe TARGET	Atorvastatin, Ezetimibe	Abant Izzet Baysal University	marketed	Statin and cholesterol absorption inhibitor combination	HMG-CoA reductase; NPC1L1 transporter
Simvastatin/Ezetimibe	Simvastatin/Ezetimibe	dr.Frank L.J. Visseren	marketed	Statin/Ezetimibe combination	HMG-CoA reductase; NPC1L1 transporter
statin + ezetimibe + Nutraceuticals	statin + ezetimibe + Nutraceuticals	University of Roma La Sapienza	marketed	Lipid-lowering combination therapy	HMG-CoA reductase; NPC1L1 transporter; multiple nutraceutical targets
Experimental: Rosuvastatin/Ezetimibe 10	Experimental: Rosuvastatin/Ezetimibe 10	Keun-Sik Hong	marketed	Statin/ezetimibe combination	HMG-CoA reductase; NPC1L1 transporter
statin + ezetimibe	statin + ezetimibe	University of Roma La Sapienza	marketed	Lipid-lowering agent combination (statin + cholesterol absorption inhibitor)	HMG-CoA reductase; NPC1L1 transporter
atorvastatin plus ezetimibe	atorvastatin plus ezetimibe	Shanghai Jiao Tong University School of Medicine	marketed	Statin plus cholesterol absorption inhibitor combination	HMG-CoA reductase; NPC1L1 transporter
statins, ezetimibe	statins, ezetimibe	Korea University Anam Hospital	marketed	HMG-CoA reductase inhibitor and cholesterol absorption inhibitor combination	HMG-CoA reductase; NPC1L1 transporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Statin and cholesterol absorption inhibitor combination class)

1. Abant Izzet Baysal University · 1 drug in this class
2. UMC Utrecht · 1 drug in this class